Immunology Investor Event
DupixentⓇ - Building a megabrand
sanofi
Indications
Clinical program²
Patients treated
Demographics
2019
4
Positive pivotal trials
in AD, Asthma and CRSwNP
COPD and EoE initiated
PN, CSU, BP planned
2022
61
7 new positive pivotal trials
12 new trials achieving FPI
7 new indications initiated
>400K
125K
adult, adolescent
adult, adolescent, pediatric
>4.9 million
biologic eligible
patients in AD
U.S. and Ex-U.S.3
>2 million
biologic eligible
patients in Asthma
and CRSWNP U.S.
and Ex-U.S.4
Geographies
20
>50
Competition
No other systemic biologic
for Type 2 approved
No other biologic with comparable
breadth and scope of data on efficacy
and safety across Type 2 indications
and age groups
1. AD (18+Y, 12-17Y, 6-11Y), Asthma (12+Y, 6-11Y), CRSWNP; 2. For 2022, 7 positive pivotal trials (1 AD 6m-5Y, 1 Asthma 6-11Y, EoEx2, PNx2, 1 CSU), 12 FPI (1 AD 6m-5Y, 1 EoE ped, PNX2, CSUx2, 1 CIndU, 1 BP, 1 AFRS, 1 COPD, 1 CRSSNP, 1 CPUO),
7 New indications (CRSSNP, AFRS, CPUO, CIndU, BP, PN, CSU) 3. Japan, Germany, France, Italy, Spain, United Kingdom and China; 4. Japan, Germany, France, Italy, Spain & United Kingdom.
18 Immunology Investor EventView entire presentation